Rhabdomyosarcoma News and Research

RSS

Houston researcher identifies new targets for fatal rhabdomyosarcoma

A cancer researcher at the University of Houston is reporting what makes malignant soft tissue cancer grow in children, identifying key mechanisms and molecular targets to prevent tumor progression in patients in future therapies of the fatal rhabdomyosarcoma.

9 Jun 2026

New biomarker predicts therapy response for hard-to-treat childhood cancers

A study by researchers at the University of Birmingham has identified a new biomarker for response to a specific cancer therapy, treating children with Ewing Sarcoma and other tumor types.

22 May 2026

Targeting super-enhancer mechanisms offers new strategies for cancer therapy

Super-enhancers (SEs) are large clusters of transcriptional regulatory elements that drive oncogene expression, maintain malignancy, and create "transcriptional addiction" in cancer.

13 Apr 2026

NCCN publishes new guidelines for management of pediatric soft tissue sarcomas

The National Comprehensive Cancer Network (NCCN) today published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Soft Tissue Sarcomas.

17 Feb 2026

Childhood cancer survival varies by tumor stage at diagnosis

A major study by UCL and Fondazione IRCCS Istituto Nazionale dei Tumori in Milan (INT) researchers has for the first time shown in detail how far children's cancer has spread at diagnosis in a way that can be compared between countries.

9 Feb 2026

Thiostrepton suppresses rhabdomyosarcoma progression by targeting the PI3K–AKT pathway

Rhabdomyosarcoma (RMS) accounts for up to 10% of childhood cancers and nearly half of pediatric soft tissue sarcomas.

30 Oct 2025

Study finds evidence for repurposing thiostrepton as an anti-rhabdomyosarcoma drug

Rhabdomyosarcoma (RMS) accounts for up to 10% of childhood cancers and nearly half of pediatric soft tissue sarcomas.

27 Oct 2025

Disrupting protein quality control slows tumor growth in pediatric rhabdomyosarcoma

A new research paper was published in Volume 16 of Oncotarget on August 29, 2025, titled "In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma."

29 Aug 2025

New insights into rare liver cancer as clinical trial for treatment begins

Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC) mounts a ferocious attack against an unlucky few-in this case, children, adolescents, and young adults.

17 Jan 2025

MPA-CF3: A marine-derived compound disrupting COPZ1 to combat EV-A71

This study is spearheaded by researcher Wu Zhong (National Engineering Research Center for the Emergence Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing) and Prof. Yong Qin (West China School of Pharmacy, Sichuan University).

26 Jun 2024

Novel immunotherapy shows promise for high-risk sarcomas: HEROS 2.0 trial results published

Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas in the journal Nature Cancer.

24 Apr 2024

Research project receives 25 million U.S. dollars to develop drugs against childhood cancers

Cancer is one of the most common causes of death in children worldwide. A research team in which the University of Würzburg is involved wants to change this – and has now received substantial funding for its work.

6 Mar 2024

Novel assay enhances pediatric cancer treatment by identifying clinically relevant gene fusions

Identification of specific gene fusions is critical for the successful targeted treatment of pediatric cancer patients.

13 Feb 2024

From Cells to Drugs: How Cell Painting is Transforming Drug Discovery

In this interview, Jordi Carreras delves into the fascinating world of Cell Painting, a powerful technology gaining momentum in drug discovery. He shares insights into his groundbreaking research, the unique aspects of Phenaros' drug discovery platform, and the synergy between academia and industry.

From ELRIG (UK) Ltd. 1 Nov 2023

Scientific breakthrough could someday save the lives of children with rhabdomyosarcoma

"Every successful medicine has its origin story. And research like this is the soil from which new drugs are born," says Cold Spring Harbor Laboratory Professor Christopher Vakoc.

28 Aug 2023

Recent advances in the understanding of the role and mechanism of CCAR2 in cancer

Researchers described the dual role of cell cycle and apoptosis regulator 2 (CCAR2) in cancer progression as a tumor suppressor and promoter.

4 Aug 2023

Researchers discover potential new treatment for rhabdomyosarcoma

Researchers from the Leibniz Institute on Aging in Jena and the Brandenburg University of Technology Cottbus-Senftenberg have discovered a novel treatment approach for soft tissue tumors, which are frequently occurring in children and are often malignant.

26 Jul 2023

Both vaccine strain and adjuvant selection are critical elements for improving the breadth of protective immunity against enterovirus D68

Researchers demonstrated the production of cross-clade neutralizing antibodies in response to EV-D68.

19 May 2023

Scientists use enhanced environmental surveillance for poliovirus type 2 detection in London sewage samples

In a new study, researchers investigated molecular properties of type 2 poliovirus (PV) isolates obtained from sewage samples (SS) to detect PV transmission in communities.

17 Oct 2022

Research identifies unique vulnerabilities in ALT cancers that can serve as novel therapeutic targets

In a study recently published in Cancer Research, a journal of the American Association for Cancer Research, a team of researchers led by C. Patrick Reynolds, M.D., Ph.D., director for the Texas Tech University Health Sciences Center School of Medicine Cancer Center, sought to expand upon his lab's previous research that showed ALT tumors identified by a biomarker known as C-circles share a common biology that confers vulnerabilities to be exploited for cancer therapy.

10 Aug 2022